Home › Compare › ORPHY vs EPRT

ORPHY vs EPRT: Dividend Comparison 2026

ORPHY yields 6666.67% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812062.00M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ORPHY vs EPRT

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + EPRT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ORPHY pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + EPRT for your $10,000?

ORPHY: 50%EPRT: 50%
100% EPRT50/50100% ORPHY
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ORPHY
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
EPRT buys
0
No recent congressional trades found for ORPHY or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYEPRT
Forward yield6666.67% ✓3.92%
Annual dividend / share$2.00 ✓$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29% ✓
Portfolio after 10y$1028095347812062.00M ✓$63.4K
Annual income after 10y$998,628,545,336,266,700,000.00 ✓$12,840.73
Total dividends collected$1026118102492338.88M ✓$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ORPHY vs EPRT ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$677,367$666,666.67$11,205$505.18+$666.2K → ORPHY
2$42,928,313$42,203,530.63$12,672$682.46+$42.92M → ORPHY
3$2,545,616,701$2,499,683,405.64$14,490$930.48+$2545.60M → ORPHY
4$141,255,910,403$138,532,100,533.89$16,786$1,282.69+$141255.89M → ORPHY
5$7,335,374,338,812$7,184,230,514,680.15$19,753$1,791.56+$7335374.32M → ORPHY
6$356,516,885,536,661$348,668,034,994,132.70$23,677$2,541.64+$356516885.51M → ORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$29,008$3,672.99+$16218956689.94M → ORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$36,463$5,425.08+$690711023145.83M → ORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$47,238$8,221.57+$27539067734387.93M → ORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$63,385$12,840.73+$1028095347812062.00M → ORPHY

ORPHY vs EPRT: Complete Analysis 2026

ORPHY — Stock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ORPHY vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.